Slater & Gordon Limited jumps 220% in 2 years, is it too late to buy?

Slater & Gordon Limited (ASX:SGH) to continue growing

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Slater & Gordon Limited (ASX: SGH) has been one of the best performing small(er) cap stocks on the ASX over the last three years. After hitting a low of $1.50 in early 2012, the legal firm's shares have staged an incredible run to trade at around $6.50 today. The 270% rise has been spectacularly rewarding for investors that held on through the negative press relating to ex-prime minister Julia Gillard and some pessimistic broker forecasts.

Outstanding Growth

Slater & Gordon has been able to grow net profit from $25 million in the 2012 financial year to over $60 million last financial year, a 145% rise on just a 90% rise in revenue. This indicates that the company is scalable and can grow profits faster than revenue, a feature that analysts expect to continue into the future.

Positive Outlook

Analysts have been pleasantly surprised by the success of the company's UK and Australian growth plans and are forecasting compound annual profit growth approaching 20% for the next two financial years.

Slater & Gordon currently trades on a trailing PE ratio of nearly 22, and an appealing forward PE ratio of 17 (2015) and 14 (2016). These forecasts are based on a continuation of the group's acquisition strategy to grow market share in the UK and Australia.

Competitive Position

Slater & Gordon have achieved such incredible results by positioning the company as the dominant personal injury lawyers in Australia. The company has since expanded to other fields and is developing an ever-increasing presence in the UK personal injury market.

Slater & Gordon employs nearly 3000 people between the two locations, which is expected to increase as its UK market share increases from around 5% currently to 10% in 2017 and 12% in 2019, according to analysts.

The UK legal market is around five times larger than the Australian market, making overseas success increasingly important to shareholders returns. Most brokers are positive about the company's chances in the UK, and Slater and Gordon conveniently keep an archive of broker research on their website for investors to review.

Another Terrific Idea

Motley Fool contributor Andrew Mudie does not own shares in any companies mentioned. You can find Andrew on Twitter @andrewmudie

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »